News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
179,084 Results
Type
Article (17260)
Company Profile (126)
Press Release (161698)
Section
Business (58028)
Career Advice (928)
Deals (9318)
Drug Delivery (32)
Drug Development (23307)
Employer Resources (70)
FDA (2309)
Job Trends (4206)
News (91893)
Policy (5758)
Tag
Academia (479)
Alliances (16105)
Alzheimer's disease (370)
Antibody-drug conjugate (ADC) (49)
Approvals (2270)
Artificial intelligence (62)
Bankruptcy (76)
Best Places to Work (2855)
Biotechnology (117)
Breast cancer (45)
Cancer (412)
Career advice (748)
CAR-T (48)
Cell therapy (144)
Clinical research (17983)
Collaboration (196)
COVID-19 (726)
C-suite (62)
Data (350)
Diabetes (34)
Diagnostics (1033)
Drug discovery (33)
Earnings (15530)
Employer resources (68)
Events (30493)
Executive appointments (153)
FDA (2420)
Funding (164)
Gene therapy (100)
GLP-1 (228)
Government (602)
Healthcare (2350)
Infectious disease (760)
Inflammatory bowel disease (52)
Interviews (135)
IPO (4038)
Job creations (1470)
Job search strategy (698)
Layoffs (131)
Legal (1170)
Lung cancer (50)
Manufacturing (87)
Medical device (670)
Medtech (671)
Mergers & acquisitions (5334)
Metabolic disorders (133)
Neuroscience (482)
NextGen Class of 2024 (1434)
Non-profit (446)
Northern California (513)
Obesity (72)
Opinion (163)
Patents (37)
People (21662)
Phase I (6989)
Phase II (8577)
Phase III (4846)
Pipeline (169)
Policy (35)
Postmarket research (301)
Preclinical (2861)
Press Release (61)
Radiopharmaceuticals (77)
Rare diseases (85)
Real estate (2427)
Recruiting (35)
Regulatory (4299)
Research institute (514)
Resumes & cover letters (151)
Series A (33)
Southern California (497)
Startups (1773)
United States (4390)
Vaccines (176)
Weight loss (62)
Date
Today (65)
Last 7 days (345)
Last 30 days (1311)
Last 365 days (12595)
2024 (11392)
2023 (13201)
2022 (16037)
2021 (16924)
2020 (13174)
2019 (9493)
2018 (7536)
2017 (8976)
2016 (8111)
2015 (9408)
2014 (9724)
2013 (9448)
2012 (6079)
2011 (6451)
2010 (5840)
Location
Africa (323)
Asia (13227)
Australia (2625)
California (1188)
Canada (442)
China (96)
Connecticut (45)
Europe (29563)
Florida (118)
Illinois (92)
Indiana (61)
Maryland (192)
Massachusetts (933)
Michigan (54)
Minnesota (89)
New Jersey (334)
New York (298)
North Carolina (245)
Northern California (513)
Ohio (41)
Pennsylvania (265)
South America (400)
Southern California (497)
Texas (119)
Washington State (225)
179,084 Results for "sqz biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company —a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them rather than using electricity.
February 29, 2024
·
3 min read
Funding
Navigating a Biotech Exit in a Rebounding Market
With climbing biotech M&A and IPO activity following the post-pandemic slump, experts offer insights on maximizing value and otherwise capitalizing on exit opportunities.
November 6, 2024
·
8 min read
·
Ana Mulero
Business
Roche Decides Not to Exercise Solid Tumor Option with SQZ
Embattled SQZ Biotechnologies announced Tuesday that the Swiss biotech will not exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program.
July 25, 2023
·
2 min read
·
Connor Lynch
Business
SQZ Biotechnologies Provides Update on Collaboration with Roche
SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced that Roche has determined that it will not exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program.
July 25, 2023
·
4 min read
Earnings
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more
BioSpace
takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
November 12, 2024
·
9 min read
·
Annalee Armstrong
Pharm Country
NYSE to Commence Delisting Proceedings Against SQZ Biotechnologies Company (SQZ)
The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of SQZ Biotechnologies Company — ticker symbol SQZ — from the NYSE.
July 3, 2023
·
1 min read
Deals
5 Radiopharma Biotechs to Watch for Potential Buyouts
Big Pharma can’t seem to get enough radiopharmaceutical biotechs. With Lilly, Sanofi and BMS chasing Novartis into the complex space, all eyes are on these specialty biotechs.
October 9, 2024
·
5 min read
·
Annalee Armstrong
Business
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial results and recent portfolio updates.
November 8, 2023
·
6 min read
Job trends
Cell Therapy Biotechs Hunt for Autoimmune Expertise in Pivot From Oncology
In a tough fundraising space, cell therapy biotechs pursuing autoimmune indications review staffing to ensure the right expertise is in place to tackle the new disease area.
November 6, 2024
·
6 min read
·
Annalee Armstrong
Genetown
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatment of Human Papillomavirus 16 positive (HB16+) driven cancers at the Society for Immunotherapy of Cancer Annual Meeting 2023.
November 3, 2023
·
4 min read
1 of 17,909
Next
